Amylin Pharmaceuticals President and COO Daniel Bradbury is taking over as CEO from Ginger L. Graham on March 1. Bradbury has been president and COO since last June.
Jitendra N. Doshi is leaving his positions as COO and CFO of Caraco Pharmaceutical Laboratories to devote his efforts to managing and overseeing Sun Pharmaceutical's development projects and overall operations at its New Jersey and Ohio facilities.
Bernard Poussot has been promoted to the position of president, COO and vice chairman at Wyeth.
Jacques van Kimmenaede has been appointed president of Diosynth Biotechnology.
Gilead Sciences has promoted Jim Meyers to senior vice president, commercial operations, North America.
Metabolon has added these three members to its executive staff: Tim Germann, the new vice president of sales; Dr. Bruce McCreedy has been appointed vice president of strategic development; and Dr. Dan Stevens is the new director of marketing. MonoGen has hired James D. Cureton for the position of vice president, sales and marketing.
Archimedes Pharma has appointed Simon Collins as U.K. country manager.
Aize Smink has joined Chiltern International as global head of project management.
BioVerdant has named Dr. Berkeley W. Cue to its scientific advisory board.
Exelixis has named Jose Baselga, M.D., to its scientific advisory board.
John Leo has resigned from his position as a member of the China Aoxing board of directors.
NexMed has named David S. Tierney, M.D. to the board of directors.
Somaxon Pharmaceuticals has appointed Robert Jones as vice president, human resources.
J. Michael Millis, M.D., has been appointed to the board of Vital Therapies.
CuraGen has appointed James Noble, M.A., C.F.A. to its board of directors.
Dr. Andrew Pecora, FACP, has joined TetraLogic Pharmaceuticals board.